Sanofi says MS treatment reduced relapse rate
PARIS (Reuters) - Sanofi said on Friday a trial of its multiple-sclerosis treatment teriflunomide found that a daily dose of the drug reduced the rate of relapse by 36 percent compared with a placebo. Teriflunomide, marketed as Aubagio, is one of the two multiple sclerosis drugs Sanofi has in late-stage development as it seeks to catch up with a fast-selling oral treatment from Novartis. The study assessed the efficiency and safety of the drug in 1,169 patients with relapsing forms of multiple sclerosis. ...
Source: news.yahoo.com
No comments:
Post a Comment